Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus PBZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus PBZ.
CHILDREN'S ALLEGRA HIVES vs PBZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antihistamine
Antihistamine